Progress of targeted therapy in multiple myeloma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.010
- VernacularTitle:多发性骨髓瘤靶向药物治疗进展:第56届美国血液学会年会报道
- Author:
Quande LIN
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Targeted therapy;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):31-33,36
- CountryChina
- Language:Chinese
-
Abstract:
With the further study on molecular pathogenesis of multiple myeloma (MM),lots of novel targeted therapies emerged into clinical trials,which improved the response rate and life quality of MM patients.In the 56th American Society of Hematology (ASH) annual meeting,a series of special reports about latest developments in targeted therapy for MM patients were published.Efficacy was improved significantly by these reagents,which may provide the new treatment strategies for MM patients.The advances in the novel targeted therapies will be summarized in this paper based on the new reports in the 56th ASH annual meeting.
